200 related articles for article (PubMed ID: 33891268)
1. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
Kim H; Cook G; Goodall S; Liew D
Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
[TBL] [Abstract][Full Text] [Related]
2. Estimation of Health-Related Utilities for
Soare IA; Leeuwenkamp O; Longworth L
Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
[TBL] [Abstract][Full Text] [Related]
3. Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy.
Bulamu NB; Vissapragada R; Chen G; Ratcliffe J; Mudge LA; Smithers BM; Isenring EA; Smith L; Jamieson GG; Watson DI;
Health Qual Life Outcomes; 2021 Oct; 19(1):233. PubMed ID: 34600554
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
Pharmacoecon Open; 2024 May; ():. PubMed ID: 38696019
[TBL] [Abstract][Full Text] [Related]
6. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
[TBL] [Abstract][Full Text] [Related]
7. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.
Pilz MJ; Seyringer S; Hallsson LR; Bottomley A; Jansen F; King MT; Norman R; Rutten MJ; Leeuw IMV; Siersema PD; Gamper EM
Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38483665
[TBL] [Abstract][Full Text] [Related]
8. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients.
Pan CW; He JY; Zhu YB; Zhao CH; Luo N; Wang P
Eur J Health Econ; 2023 Aug; 24(6):885-893. PubMed ID: 36083356
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
10. French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30.
Nerich V; Gamper EM; Norman R; King M; Holzner B; Viney R; Kemmler G
Appl Health Econ Health Policy; 2021 Mar; 19(2):191-202. PubMed ID: 32537694
[TBL] [Abstract][Full Text] [Related]
11. Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D.
Jansen F; Verdonck-de Leeuw IM; Gamper E; Norman R; Holzner B; King M; Kemmler G;
Qual Life Res; 2021 Jul; 30(7):2009-2019. PubMed ID: 33512653
[TBL] [Abstract][Full Text] [Related]
12. Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.
King MT; Viney R; Simon Pickard A; Rowen D; Aaronson NK; Brazier JE; Cella D; Costa DSJ; Fayers PM; Kemmler G; McTaggart-Cowen H; Mercieca-Bebber R; Peacock S; Street DJ; Young TA; Norman R;
Pharmacoeconomics; 2018 Feb; 36(2):225-238. PubMed ID: 29270835
[TBL] [Abstract][Full Text] [Related]
13. Japanese value set for the EORTC QLU-C10D: A multi-attribute utility instrument based on the EORTC QLQ-C30 cancer-specific quality-of-life questionnaire.
Shiroiwa T; King MT; Norman R; Müller F; Campbell R; Kemmler G; Murata T; Shimozuma K; Fukuda T
Qual Life Res; 2024 Jul; 33(7):1865-1879. PubMed ID: 38724771
[TBL] [Abstract][Full Text] [Related]
14. United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument.
Revicki DA; King MT; Viney R; Pickard AS; Mercieca-Bebber R; Shaw JW; Müller F; Norman R
Med Decis Making; 2021 May; 41(4):485-501. PubMed ID: 33813946
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
16. Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values.
van Gelder T; Mulhern B; Schoormans D; Husson O; De Abreu Lourenço R
Qual Life Res; 2020 Jun; 29(6):1483-1494. PubMed ID: 31938965
[TBL] [Abstract][Full Text] [Related]
17. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
18. The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30.
McTaggart-Cowan H; King MT; Norman R; Costa DSJ; Pickard AS; Regier DA; Viney R; Peacock SJ
MDM Policy Pract; 2019; 4(1):2381468319842532. PubMed ID: 31245606
[No Abstract] [Full Text] [Related]
19. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
20. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
